Everything below concerns GLP-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Research mainly focuses on polymers that show thermoresponsivity in aqueous solution. Promising areas of application are tissue engineering, liquid chromatography, drug delivery and bioseparation. Only a few commercial applications exist, for example, cell culture plates coated with an LCST-polymer.
==== Physiological effects ==== Angiotensin II exhibits endocrine, autocrine/paracrine, and intracrine functions. It promotes aldosterone release from the adrenal cortex, as well as arginine vasopressin release from the posterior pituitary. It acts directly upon the proximal tubules of the kidney to regulate water and Na+ reabsorption, promoting reabsorption at very low concentrations while increasingly inhibiting reabsorption with increasing concentrations. In the proximal tubule, it promotes Na+ reabsorption and H+ excretion (which is coupled to bicarbonate reabsorption) by the Na+/H+ exchanger. It causes venous and arterial vasoconstriction by a Gq alpha subunit-coupled receptor upon vascular smooth muscle cells (with downstream IP3-dependent mechanism causing a rise in intracellular Ca2+ to effect smooth muscle excitation-contraction coupling), thus acting to increase blood pressure.
== Early life and education == Melo was born on 24 July 1958. He was born and raised in Piracanjuba, in the interior of the state of Goiás. He moved to Porto Alegre in February 1978. He is married to Valéria Leopoldino, with whom he has two children: Pablo Melo and João Arthur. He graduated with a law degree from Unisinos.
== History == Olaratumab was originally developed by ImClone Systems, which was acquired by Eli Lilly in 2008. A Phase I clinical trial was conducted in Japanese patients in September 2010, followed by a Phase II trial in 133 patients, starting in October 2010. In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorisation, based on the mentioned Phase II study, valid throughout the European Union on 9 November 2016. Previously considered a promising drug, the FDA granted olaratumab fast track designation, breakthrough therapy designation and priority review status. In October 2016, the US FDA issued an accelerated approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft-tissue sarcoma, based on the same study. A phase III trial completed in 2019, and unfortunately showed no benefit from the addition of olaratumab to doxorubicin. As noted above, these results led to withdrawal of approval in the United States and Europe.
Headquarters Großdeutschland Reconnaissance Battalion Großdeutschland Panzer Regiment Großdeutschland Grenadier Regiment Großdeutschland Fusilier Regiment Großdeutschland Engineer Battalion Großdeutschland Artillery Regiment Großdeutschland Tank Destroyer Battalion Großdeutschland Army Anti-Aircraft Battalion Großdeutschland Assault Gun Battalion Großdeutschland Signal Battalion Großdeutschland Divisional Supply Group
Sources: en.wikipedia.org
== Vitamin B12 == Vitamin B12 plays an integral role in this reaction. Coenzyme B12 (adenosyl-cobalamin) is an organometallic form of vitamin B12 and serves as the cofactor of Methylmalonyl-CoA mutase, which is an essential enzyme in the human body. The transformation of Methylmalonyl-CoA to Succinyl-CoA by this enzyme is a radical reaction.
Some hormonal birth control methods utilize cervical drug delivery methods. The earliest example of such dates to 1850 Ancient Egypt when acadia gum was inserted into the vagina, releasing spermicidal components. Examples in the modern era include vaginal rings and intrauterine devices (IUDs) that release hormones into the reproductive system to prevent fertilization. Vaginal rings are plastic ring-shaped devices that are inserted into the vaginal canal and slowly release hormones such as estradiol or progestin. Hormonal IUDs are T-shaped devices inserted into the uterus, releasing progestin over extended periods of time. These hormones work to thicken the cervical mucus to prevent sperm from penetrating and reaching the fallopian tubes. Copper IUDs are another form of intrauterine devices that release copper ions instead of hormones. The copper ions are toxic to sperm and therefore prevents successful fertilization.
Two different kinds of blank may be measured: a sample of dead carbon that has undergone no chemical processing, to detect any machine background, and a sample known as a process blank made from dead carbon that is processed into target material in exactly the same way as the sample which is being dated. Any 14C signal from the machine background blank is likely to be caused either by beams of ions that have not followed the expected path inside the detector or by carbon hydrides such as 12CH2 or 13CH. A 14C signal from the process blank measures the amount of contamination introduced during the preparation of the sample. These measurements are used in the subsequent calculation of the age of the sample.
Biosimilar insulins, which have a shorter development timeline of about eight years compared to 12 years for novel biologic drugs, provide a more affordable alternative, with development costs ranging from 10% to 20% of those for new biologics. These products could help improve access to treatment and reduce disparities in insulin availability. The global market for biologic medicines, including insulin, grew from $46 billion in 2002 to $390 billion in 2020, accounting for 28% of the global pharmaceutical market. In the United States, biologics represented 43% of drug expenditures, totaling $211 billion in 2019, with biosimilar spending expected to rise from $5.2 billion in 2019 to nearly $27 billion by 2024. In Europe, biologics accounted for 34% of medicine spending, reaching US$78.6 billion in 2021, with the biosimilar market valued at $8.8 billion. The global human insulin market was valued at $22.9 billion in 2020, while the biosimilar insulin market stood at $2.3 billion, projected to grow to $5.6 billion by 2027. The introduction of biosimilar insulins has increased market competition, offering a cost-effective alternative that could lower treatment costs and reduce strain on healthcare systems. Since the approval of the first biosimilar insulin, interest in the products has increased. However, uncertainty regarding their safety and efficacy has slowed their adoption among healthcare professionals.
In the bulk aqueous phase, surfactants form aggregates, such as micelles, where the hydrophobic tails form the core of the aggregate and the hydrophilic heads are in contact with the surrounding liquid. Other types of aggregates can also be formed, such as spherical or cylindrical micelles or lipid bilayers. The shape of the aggregates depends on the chemical structure of the surfactants, namely the balance in size between the hydrophilic head and hydrophobic tail. A measure of this is the hydrophilic-lipophilic balance (HLB). Surfactants reduce the surface tension of water by adsorbing at the liquid-air interface. The relation that links the surface tension and the surface excess is known as the Gibbs isotherm.
Sources: en.wikipedia.org
== Bibliography == Greenwood NN, Earnshaw A (1997). Chemistry of the Elements (2nd ed.). Butterworth-Heinemann. ISBN 978-0-08-037941-8. Holleman AF, Wiberg E, Wiberg N (2007). "Potassium". Lehrbuch der Anorganischen Chemie (in German) (91–100 ed.). Walter de Gruyter. ISBN 978-3-11-017770-1. Schultz H, Bauer G, Schachl E, Hagedorn F, Schmittinger P (2006). "Potassium compounds". Ullmann's Encyclopedia of Industrial Chemistry. Vol. A22. pp. 39–103. doi:10.1002/14356007.a22_031.pub2. ISBN 978-3-527-30673-2. National Nutrient Database Archived 2014-08-10 at the Wayback Machine at USDA Website
=== 3rd generation cephalosporins === The majority of third generation cephalosporins have the aminothiazole group at position C-7. Different groups are found at the 7-α-position like 7-α-iminohydroxy and 7-α-iminomethoxy groups. Ceftibuten however possesses a 7-α-ethylidene group. This group gives ceftibuten higher resistance to enhanced spectrum β-lactamases. Many of the oral third generation cephalosporins are esters of parenteral forms and are hydrolysed by esterases in the digestive tract (cefteram pivoxil). Some of the third generation drugs can be absorbed orally without the need of esterification. This is for example done with cefixime and cefdinir by putting a vinyl group in the C-3 position.
Romania has attracted increasing amounts of foreign investment following the end of communism, with the stock of foreign direct investment (FDI) in Romania rising to €83.8 billion in June 2019. Romania's FDI outward stock (an external or foreign business either investing in or purchasing the stock of a local economy) amounted to $745 million in December 2018, the lowest value among the 28 EU member states. Since 1867 the official currency has been the Romanian leu ("lion"), which "was redenominated, with the exchange rate set at 1 new leu = 10,000 old lei" in 2005 according to the National Bank of Romania. As it joined the EU in 2007, Romania plans to adopt the euro in 2029.
The Cossacks of Zaporizhzhia, centered on the lower bends of the Dnieper, in the territory of modern Ukraine, with the fortified capital of Zaporozhian Sich. They were given significant autonomous privileges, operating as an autonomous state (the Zaporozhian Host) within the Polish-Lithuanian Commonwealth, by a treaty with Poland in 1649. The Don Cossack State, on the River Don. Its capital was initially Razdory, then it was moved to Cherkassk, and later to Novocherkassk. There are also references to less well-known Tatar Cossacks, including the Nağaybäklär and Meshchera-speaking Volga Finns, of whom Sary Azman was the first Don ataman. It is a strange, conflicting report that these groups were assimilated by the Don Cossacks since the Turks were Muslim, the Cossack Orthodox Christian. It could be the assimilation took place in the event of raiding opposing tribes and the taking of slaves. Some are reported to have had their own irregular Bashkir and Meshchera Host up to the end of the 19th century. The Kalmyk and Buryat Cossacks also deserve mention.
Chestnuts can vary widely in shade and different terms are sometimes used to describe these shades, even though they are genetically indistinguishable. Collectively, these coat colors are usually called "red" by geneticists.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。